RTP Mobile Logo
Striving for Consensus: The Application of New Research Findings in the Management of Hodgkin and Non-Hodgkin Lymphoma
Released June 2012

Roundtable participants include Drs Jonathan W Friedberg, Steven M Horwitz, Brad S Kahl, Mark S Kaminski, John P Leonard, Craig Moskowitz, Mitchell R Smith and Anas Younes. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative disorders and is one of the most rapidly evolving fields in hematology and oncology. In contrast, Hodgkin lymphoma (HL) is a rarer disease that is relatively chemosensitive and often curable when treated appropriately. However, care for patients who do not respond to primary treatment or those with relapsed or refractory HL remains a significant challenge for oncology clinicians. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of these advances. This program uses a roundtable discussion with leading clinical investigators to assist practicing clinicians in formulating up-to-date clinical management strategies for NHL, HL and chronic lymphocytic leukemia (CLL).

    LEARNING OBJECTIVES
    • Use case-based learning to formulate individualized strategies for the care of patients with lymphoma.
    • Integrate practice-changing clinical trial results recently reported with the antibody-drug conjugate brentuximab vedotin into the evidence-based treatment algorithm for patients with relapsed/refractory HL and systemic anaplastic large cell lymphoma.
    • Utilize available research evidence on the use of CNS prophylaxis to guide treatment decision-making for patients with diffuse large B-cell lymphoma.
    • Appraise recent data on therapeutic advances and changing practice standards in follicular lymphoma, and apply this information to clinical practice.
    • Develop an algorithm for the evaluation and treatment of newly diagnosed and relapsed/refractory CLL.
    • Devise an approach for the sequential systemic treatment of cutaneous T-cell lymphoma.
    • Communicate the existing and emerging roles of proteasome inhibitors and IMiDs to patients with mantle-cell lymphoma.
    • Facilitate patient access to clinical trial participation through communication of ongoing research opportunities.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains an audio component. The participant should review the CME information and listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FriedbergAdvisory Committee: Cephalon Inc, Genentech BioOncology; Consulting Agreement: Mundipharma International Limited; Data and Safety Monitoring Board: Lilly USA LLC; Paid Research: Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. Dr HorwitzAdvisory Committee: Allos Therapeutics, Celgene Corporation; Consulting Agreements: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Kyowa Hakko Kirin Co Ltd, Seattle Genetics, Spectrum Pharmaceuticals Inc; Paid Research: Allos Therapeutics, Celgene Corporation, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc. Dr KahlAdvisory Committee: Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company. Dr KaminskiConsulting Agreement: Allos Therapeutics; Paid Research and Patent Holder: GlaxoSmithKline. Dr LeonardConsulting Agreements: Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company. Dr MoskowitzAdvisory Committee: Cephalon Inc, Genentech BioOncology, Seattle Genetics; Paid Research: Cephalon Inc, Genentech BioOncology, Lilly USA LLC, Plexxikon Inc, Seattle Genetics. Dr SmithAdvisory Committee: Cephalon Inc; Speakers Bureau: Allos Therapeutics, Cephalon Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc. Dr YounesAdvisory Committee: Allos Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi, Spectrum Pharmaceuticals Inc; Paid Research: Novartis Pharmaceuticals Corporation, Sanofi.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Seattle Genetics and Spectrum Pharmaceuticals Inc.


    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2012
    Expiration date: June 2013

     

Acknowledge and close

Listen to audio:
Striving for Consensus: The Application of New Research Findings in the Management of Hodgkin and Non-Hodgkin Lymphoma
Released June 2012

Roundtable participants include Drs Jonathan W Friedberg, Steven M Horwitz, Brad S Kahl, Mark S Kaminski, John P Leonard, Craig Moskowitz, Mitchell R Smith and Anas Younes. (Audio Content)

Read print: